 UNIONDALE, N.Y., March 30, 2021 GLOBE NEWSWIRE -- Angion Biomedica Corp. NASDAQ:ANGN, a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2020. 